QualityStocks.net News – Mymetics Corp. (MYMX.OB) Acquires Malaria Vaccine, Pursuing European Union Regulations

At www.QualityStocks.Net you can sign up for Quality Stock's Daily Newsletter to find out what Small-Cap and Micro-Cap online Investment Newsletters are interested in, plus hear about the latest news from our clients as well as other publicly traded companies.

We would like to highlight Mymetics Corp. (OTCBB: MYMX). The company is a biotechnology company developing prophylactic vaccines that combine innovative antigen engineering, minimal human protein homologies and virosome technology, a technology licensed from Pevion Biotech. Mymetics’ vaccine approach focuses on eliciting immune protection capable of interfering with late events of pathogen transmission, coupled, most importantly, with early events of pathogen transmission, such as preventing the entry across the mucosal tissues that are very often the primary entry door of most of the pathogens.

In the Company’s recent news,

Mymetics Corp. (OTCBB: MYMX) announced the acquisition of a malaria vaccine from Previon Biotech AG, a privately owned Swiss biopharmaceutical company. The preventative vaccine was successfully completed in human clinical trial phases I and II in Switzerland and the UK; more studies are to follow.

“We are pleased with this acquisition which allows us to start feeding a pipeline of products for the future, in addition to our preventive HIV/AIDS vaccine,” Christian J. F. Rochet, CEO and president of Mymetics Corp. stated in the press release. “There is a pressing need within the global community for a malaria vaccine. Annually, there are between three hundred and five hundred million people suffering from malaria with a mortality rate of approximately two million, mostly children.”

The clinical trials resulted in two of four contemplated antigens. New trials will be conducted as the company completes its application for approval of the vaccine, in compliance with European Union regulations. A clinical trial has already commenced in Tanzania to use the protocol for children and teenagers where the risk of malaria is an endemic problem; phase I and II clinical trials with all four antigens is scheduled to follow.

“The clinical trial results proved very promising,” Sylvain Fleury, Ph.D, Mymetics CSO and director, stated. “Our vaccine philosophy is to focus the immune response on relevant regions of the parasite proteins by designing specific peptides, while irrelevant and immunodistractive parts have been removed. We also believe that the vaccine efficacy will be improved by targeting both parasite forms during the infectious cycle, instead of the classical strategy to target only one of the maturation stages.”

Ernst Lübke, the company’s CFO and director, said that aside from the health advantages of Previon, the vaccine poses little threat to shareholders because half of the acquisition price is related to upcoming milestones payable in 2009 and 2010.

“This is a deal that makes sense medically, economically and institutionally,” stated Lübke.

About QualityStocks

QualityStocks.net, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks.net is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks.net website: http://Disclaimer.QualityStocks.net 

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.